Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy

Fig. 3

Analysis of the uptake mechanism of nanoparticles (NPs) in SMMC-7721/gefitinib cells. a Fluorescence spectrum analysis of the uptake of RhoB -labeled NPs and RhoB-labeled mAb MDR1-NPs in SMMC-7721/gefitinib cells. ###P < 0.001, vs RhoB-labeled NPs at different time interval. b Fluorescence spectrum analysis of the uptake of RhoB-labeled mAb MDR1-NPs in gefitinib-resistant cells with or without free mAb MDR1. ###P < 0.001, vs RhoB-labeled mAb MDR1-NPs in gefitinib-resistant cells without free mAb MDR1 at different time interval. c Fluorescence spectrum analysis of the uptake of RhoB -labeled NPs in gefitinib-resistant cells with or without free mAb MDR1. d Effects of endocytic inhibitors on the uptake ability of the two NPs in SMMC-7721/gefitinib cells. ***P < 0.001, vs RhoB-labeled NPs treated with chlorpromazine. ###P < 0.001, vs the RhoB-labeled mAb MDR1-NPs treated with chlorpromazine. The results of all experiments were expressed as mean ± SD (n = 3)

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us